Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT05365672RecruitingPhase 2
Donor immune cell therapy during live kidney transplant
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
BerlinAges 18–69 - NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70 - NCT06482450Recruiting
Improving vaccine acceptance with decision support for patients and providers
This trial tests if sending reminders and decision-support tools to patients and their doctors before appointments can increase vaccine acceptance. It focuses on families with children visiting a specific clinic in Atlanta.
Atlanta, GeorgiaAges Any age - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT06486779Recruiting
Study of Kesimpta in Greek MS Patients
This study watches how well Kesimpta (ofatumumab) works for people with relapsing multiple sclerosis over time. It collects information from routine doctor visits and scans to see if the treatment is controlling the disease.
Athens, AtticaAges 18–55 - NCT07132112RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune disease
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Nantong, JiangsuAges 18–65 - NCT06529536RecruitingPhase 4
Personalized tacrolimus dosing for children after transplant
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
Melbourne, VictoriaAges 1–18 - NCT06354179RecruitingPhase 4
Once-daily immunosuppression after liver transplant
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
BesançonAges 18 years+ - NCT04737317Recruiting
Check criteria to diagnose cardiac sarcoidosis
This study tests how doctors can best tell whether someone has cardiac sarcoidosis, a condition where inflammation affects the heart. It may help you get a more accurate diagnosis using expert guidelines and special heart tests, and it groups patients as proven, probable, or unlikely.
LeipzigAges 18 years+ - NCT06336863Enrolling by invitation
DNA test to help kidney transplant patients switch to a single anti-rejection drug
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Dallas, TexasAges 18 years+ - NCT06440525RecruitingPhase 2
Testing RSLV-132 for Sjögren's disease in women
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT06354322Recruiting
Genetic study for unclassified autoinflammatory disease or AA amyloidosis
This study looks for genetic causes of hard-to-diagnose autoinflammatory diseases or a related condition called AA amyloidosis. It aims to find answers for people whose condition does not fit any known type, by studying their genes and medical history.
ParisAges 3–80 - NCT06148025RecruitingPhase 4
Do antibiotics affect vaccine responses?
This study looks at whether taking a short course of antibiotics can change how your body responds to two vaccines (BCG and yellow fever). It may help researchers find ways to make vaccines work better.
Adelaide, South AustraliaAges 18–35 - NCT02257892Recruiting
Study of rare immune system genetic disorders
This study looks for genetic causes of immune problems, such as unusually frequent infections, abnormal allergies, or autoimmune or inflammation conditions. It may help by improving how doctors understand these disorders and by matching families with possible genetic diagnoses.
Bethesda, MarylandAges 3–99 - NCT05754450RecruitingPhase 3
Extension study for AVTX-803 in LAD type II
This trial is a follow-up study testing whether AVTX-803 continues to be safe and effective for people with Leukocyte Adhesion Deficiency type II (LAD II). If you already took part in an earlier AVTX-803 LAD II study, this may be the next step while researchers monitor benefits and side effects.
Rochester, MinnesotaAges 6 months–75 years - NCT07136389RecruitingPhase 1
Testing 2 drugs for active lupus skin disease
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Saint PetersburgAges 18–70 - NCT07641426RecruitingPhase 1/Phase 2
CID-103 Treatment for Kidney Transplant Rejection
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06860633RecruitingPhase 4
Efgartigimod for worsening myasthenia gravis in hospital
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Aurora, ColoradoAges 18 years+ - NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT07632040Enrolling by invitation
Diet changes for chronic hives in teens
This study tests whether avoiding certain foods and food additives can reduce chronic hives (itchy welts on skin) in children and teenagers. Researchers will have participants follow a special diet and track their symptoms over time.
Istanbul, FatihAges 1–18 - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.